PAVM Quote, Financials, Valuation and Earnings

Electromed has a net margin of -1105.92% compared to PAVmed's net margin of 12.06%. PAVmed's return on equity of -- beat Electromed's return on equity of 16.57%.

PAVmed has a consensus price target of $11.50, signalling upside risk potential of 1900%. On the other hand Electromed has an analysts' consensus of $33.50 which suggests that it could grow by 81.87%. Given that PAVmed has higher upside potential than Electromed, analysts believe PAVmed is more attractive than Electromed.

PAVmed has a beta of 1.060, which suggesting that the stock is 5.988% more volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

PAVmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PAVmed pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

PAVmed quarterly revenues are $8K, which are smaller than Electromed quarterly revenues of $15.7M. PAVmed's net income of $19M is higher than Electromed's net income of $1.9M. Notably, PAVmed's price-to-earnings ratio is 0.82x while Electromed's PE ratio is 23.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PAVmed is 8.46x versus 2.69x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX has a net margin of -1105.92% compared to PAVmed's net margin of -14.17%. PAVmed's return on equity of -- beat IRIDEX's return on equity of -218.69%.

PAVmed has a consensus price target of $11.50, signalling upside risk potential of 1900%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 86.92%. Given that PAVmed has higher upside potential than IRIDEX, analysts believe PAVmed is more attractive than IRIDEX.

PAVmed has a beta of 1.060, which suggesting that the stock is 5.988% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.566, suggesting its less volatile than the S&P 500 by 43.407%.

PAVmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PAVmed pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

PAVmed quarterly revenues are $8K, which are smaller than IRIDEX quarterly revenues of $11.9M. PAVmed's net income of $19M is higher than IRIDEX's net income of -$1.7M. Notably, PAVmed's price-to-earnings ratio is 0.82x while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PAVmed is 8.46x versus 0.36x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -1105.92% compared to PAVmed's net margin of -35.24%. PAVmed's return on equity of -- beat Myomo's return on equity of -38.11%.

PAVmed has a consensus price target of $11.50, signalling upside risk potential of 1900%. On the other hand Myomo has an analysts' consensus of $8.70 which suggests that it could grow by 346.15%. Given that PAVmed has higher upside potential than Myomo, analysts believe PAVmed is more attractive than Myomo.

PAVmed has a beta of 1.060, which suggesting that the stock is 5.988% more volatile than S&P 500. In comparison Myomo has a beta of 1.389, suggesting its more volatile than the S&P 500 by 38.863%.

PAVmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PAVmed pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

PAVmed quarterly revenues are $8K, which are smaller than Myomo quarterly revenues of $9.8M. PAVmed's net income of $19M is higher than Myomo's net income of -$3.5M. Notably, PAVmed's price-to-earnings ratio is 0.82x while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PAVmed is 8.46x versus 1.97x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of -1105.92% compared to PAVmed's net margin of -77.93%. PAVmed's return on equity of -- beat Stereotaxis's return on equity of -174.6%.

PAVmed has a consensus price target of $11.50, signalling upside risk potential of 1900%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 88.29%. Given that PAVmed has higher upside potential than Stereotaxis, analysts believe PAVmed is more attractive than Stereotaxis.

PAVmed has a beta of 1.060, which suggesting that the stock is 5.988% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.440, suggesting its more volatile than the S&P 500 by 43.964%.

PAVmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PAVmed pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

PAVmed quarterly revenues are $8K, which are smaller than Stereotaxis quarterly revenues of $7.5M. PAVmed's net income of $19M is higher than Stereotaxis's net income of -$5.8M. Notably, PAVmed's price-to-earnings ratio is 0.82x while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PAVmed is 8.46x versus 7.49x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.